Key facts

Invented name
  • Eperzan
  • Eperzan
Active Substance
Albiglutide
Therapeutic area
Endocrinology-Gynaecology-Fertility-Metabolism
Decision number
P/0272/2016
PIP number
EMEA-001175-PIP01-11-M04
Pharmaceutical form(s)
Powder and solvent for solution for injection
Condition(s) / indication(s)
Treatment of type II diabetes mellitus
Route(s) of administration
Subcutaneous use
Contact for public enquiries

Glaxo Group Limited

E-mail: eu.paediatrics-plans@gsk.com
Tel. +1 4388998201

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

P/0272/2016: EMA decision of 7 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for albiglutide (Eperzan), (EMEA-001175-PIP01-11-M04)

How useful do you find this page?